Cullinan Therapeutics to present interim Phase 3 REZILIENT3 trial results at WCLC26

Cullinan Therapeutics to present interim Phase 3 REZILIENT3 trial results at WCLC26
Cullinan Therapeutics reveals trial update

Cullinan Therapeutics announced it will present interim results from its Phase 3 REZILIENT3 trial at the International Association for the Study of Lung Cancer’s WCLC26 conference.

The study evaluates first-line zipalertinib in combination with chemotherapy in partnership with Taiho Oncology and Taiho Pharmaceutical. The upcoming presentation is expected to provide new insights into the company's lung cancer treatment strategy.

Cullinan Therapeutics recently scheduled a webcast in September to present Phase 3 REZILIENT3 trial results on zipalertinib plus chemotherapy, according to a company announcement. Earlier this year, the company participated in the ITP Conference 2026 to build stronger relationships within the rare disease community, as reported previously. These initiatives reflect Cullinan's ongoing engagement with clinical stakeholders and communication of trial developments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.